Afatinib: A review of its use in the treatment of advanced non-small cell lung cancer

Drugs

Volumn 74, Issue 2, 2014, Pages 207-221

  Keating, Gillian M ^a  

^a NONE   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; ALANINE AMINOTRANSFERASE; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; PEMETREXED; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ACNE; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER SURVIVAL; CANCER THERAPY; CHEILITIS; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG INTERACTION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRY SKIN; EPISTAXIS; FATIGUE; HUMAN; LEUKOCYTE COUNT; LEUKOPENIA; LUNG ADENOCARCINOMA; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; PARONYCHIA; PHARMACODYNAMICS; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; STOMATITIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; VOMITING; ANTAGONISTS AND INHIBITORS; CANCER GRADING; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; PATHOLOGY;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; NEOPLASM GRADING; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84895766506     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0170-8     Document Type: Article

References (58)

1. Liao B-C, Lin C-C, Yang JC-H. First-line management of EGFR-mutated advanced lung adenocarcinoma: recent developments. Drugs. 2013;73(4):357-69.
2. Bonanno L, Favaretto A, Rugge M. Role of genotyping in non-small cell lung cancer treatment: current status. Drugs. 2011;71(17):2231-46.
3. National Comprehensive Cancer Network. Non-small cell lung cancer: NCCN clinical practice guidelines in oncology (version 1.2014). 2013. http://www.nccn.org/professionals/physician-gls/pdf/nscl.pdf. Accessed 22 Oct 2013.
4. Metro G, Crinò L. The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer. Expert Rev Anticancer Ther. 2011;11(5):673-82.
5. Hirsh V. Afatinib (BIBW 2992) development in non-small-cell lung cancer. Future Oncol. 2011;7(7):817-25.
6. Nelson V, Ziehr J, Agulnik M, et al. Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC. Onco Targets Ther. 2013;6:135-43.
7. Bordoni RE. Afatinib (BIBW-2992): a novel dual EGFR/HER2neu inhibitor with promising activity in non-small-cell lung cancer. Therapy. 2011;8(1):15-22.
8. Brugger W, Thomas M. EGFR-TKI resistant non-small cell lung cancer (NSCLC): new developments and implications for future treatment. Lung Cancer. 2012;77(1):2-8.
9. ®) in Asian and non-Asian lung cancer patients [media release]. 2013. http://www.boehringer- ingelheim.com/news/news-releases/press-releases/2013/27-october-2013-oncology. html. Accessed 2 Dec 2013.
10. European Medicines Agency. Giotrif (afatinib) film-coated tablets: EU summary of product characteristics. 2013. http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Product-Information/human/002280/WC500152392.pdf. Accessed 18 Oct 2013.
11. Boehringer Ingelheim Pharmaceuticals Inc. Gilotrif™ (afatinib) tablets for oral use: US prescribing information. 2013. http://www.accessdata. fda.gov/drugsatfda-docs/label/2013/201292s000lbl.pdf. Accessed 15 Oct 2013.
12. QIAGEN N.V. QIAGEN submits companion diagnostic to FDA to guide treatment decisions for new investigational lung cancer compound [media release]. 2013. http://www.qiagen.com. Accessed 23 Oct 2013.
13. QIAGEN N.V. QIAGEN receives FDA approval for therascreen® EGFR RGQ PCR Kit as a companion diagnostic for lung cancer patients [media release]. 2013. http://www.qiagen.com. Accessed 23 Oct 2013.
14. Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 2008;27(34):4702-11.
15. Solca F, Dahl G, Zoephel A, et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther. 2012;343(2):342-50.
16. Chen G, Kronenberger P, Teugels E, et al. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. BMC Med. 2012;10:28.
17. Takezawa K, Okamoto I, Tanizaki J, et al. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor. Mol Cancer Ther. 2010;9(6):1647-56.
18. Furuyama K, Harada T, Iwama E, et al. Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors. Cancer Sci. 2013;104(5):584-9.
19. Ninomiya T, Takigawa N, Ichihara E, et al. Afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model. Mol Cancer Ther. 2013;12(5):589-97.
20. Kim Y, Ko J, Cui Z-Y, et al. The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor. Mol Cancer Ther. 2012;11(3):784-91.
21. Regales L, Gong Y, Shen R, et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest. 2009;119(10):3000-10.
22. Kim SM, Kwon O-J, Hong YK, et al. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation. Mol Cancer Ther. 2012;11(10):2254-64.
23. Chen G, Noor A, Kronenberger P, et al. Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib. PLoS One. 2013;8(3):e59708.
24. Molife LR, Rudman SM, Alam S, et al. Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors. Cancer Chemother Pharmacol. 2013;72(6):1213-22.
25. Eskens FALM, Mom CH, Planting AST, et al. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer. 2008;98(1):80-5.
26. Marshall J, Hwang J, Eskens FALM, et al. A phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors. Invest New Drugs. 2013;31(2):399-408.
27. Yap TA, Vidal L, Adam J, et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol. 2010;28(25):3965-72.
28. Gordon MS, Mendelson DS, Gross M, et al. A phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors. Invest New Drugs. 2013;31(2):409-16.
29. Kristeleit H, Puglisi M, Middleton GW, et al. Phase II, open-label trial to assess the effect of continuous oral afatinib (BIBW 2992) at a daily dose of 50 mg on QTc, pharmacokinetics, and efficacy in relapsed or refractory solid tumors including brain metastases and glioblastoma that is not amenable to other therapy [abstract no. 2613]. J Clin Oncol. 2011;29(15 Suppl 1).
30. Wind S, Schmid M, Erhardt J, et al. Pharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours. Clin Pharmacokinet. 2013;52(12):1101-9.
31. Sequist LV, Yang JC-H, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327-34.
32. Stopfer P, Marzin K, Narjes H, et al. Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers. Cancer Chemother Pharmacol. 2012;69(4):1051-61.
33. Agus DB, Terlizzi E, Stopfer P, et al. A phase I dose escalation study of BIBW 2992, and irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumours [abstract]. J Clin Oncol. 2006;24(18S):2074.
34. Yang JC-H, Shih J-Y, Su W-C, et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol. 2012;13(5):539-48.
35. Wu YL, Zhou C, Hu C-P, et al. LUX-Lung 6: a randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung [abstract no. 8016]. J Clin Oncol. 2013;31(15 Suppl) (plus poster presented at the 49th Annual Meeting of the American Society of Clinical Oncology; 31 May-4 Jun 2013; Chicago (IL)).
36. Yang JC-H, Hirsh V, Schuler M, et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3342-50.
37. Geater SL, Zhou C, Hu C-P, et al. LUX-Lung 6: patient-reported outcomes (PROs) from a randomized open-label, phase III study in first-line advanced NSCLC patients (pts) harboring epidermal growth factor receptor (EGFR) mutations [abstract no. 8061]. J Clin Oncol. 2013;31(15 Suppl) (plus poster presented at the 49th Annual Meeting of the American Society of Clinical Oncology; 31 May-4 Jun 2013; Chicago (IL)).
38. Yang JC, Schuler M, Yamamoto N, et al. Activity of afatinib in uncommon epidermal growth factor receptor (EGFR) mutations in LUX-Lung 3, a phase III trial of afatinib or cisplatin/pemetrexed in EGFR mutation-positive lung cancer [abstract no. 1252P]. Ann Oncol. 2012;23(Suppl 9):ix410-1.
39. Yang JC-H, Sequist LV, Geater SL, et al. Activity of afatinib in uncommon epidermal growth factor receptor (EGFR) mutations: findings from three trials of afatinib in EGFR mutation-positive lung cancer [abstract no. O03.05 plus slide presentation]. 15th World Conference on Lung Cancer; 27-30 Oct 2013; Sydney.
40. Mok T, Schuler M, Yamamoto N, et al. LUX-Lung 3: afatinib vs. cisplatin and pemetrexed in Asian patients with adenocarcinoma of the lung harbouring an epidermal growth factor receptor mutation [abstract no. HO-003]. 5th Asia Pacific Lung Cancer Conference; 26-28 Nov 2012; Fukuoka.
41. Yamamoto N, Schuler M, O'Byrne K, et al. LUX-Lung 3: afatinib vs. cisplatin and pemetrexed in Japanese patients with adenocarcinoma of the lung harbouring an EGFR mutation [abstract no. PLS-6]. Ann Oncol. 2012;23(Suppl 11):xi8.
42. Schuler M, Yang JC-H, Sequist LV, et al. Efficacy of afatinib vs. chemotherapy in treatment-naïve patients with non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations with or without metastatic brain disease [abstract no. MO07.13 plus slide presentation]. 15th World Conference on Lung Cancer; 27-30 Oct 2013; Sydney.
43. Yang JC-H, Sequist LV, O'Byrne KJ, et al. Epidermal growth factor receptor (EGFR)-mediated adverse events in patients with EGFR mutation-positive non-small cell lung cancer (NSCLC) treated with afatinib [abstract no. 895]. Eur J Cancer. 2013;49(Suppl 2):S190 (plus poster presented at European Cancer Congress 2013; 27 Sep-1 Oct 2013; Amsterdam).
44. Yang JC-H, Reguart N, Barinoff J, et al. Diarrhea associated with afatinib: an oral ErbB family blocker. Expert Rev Anticancer Ther. 2013;13(6):729-36.
45. Lacouture ME, Schadendorf D, Chu C-YC, et al. Dermatologic adverse events associated with afatinib: an oral ErbB family blocker. Expert Rev Anticancer Ther. 2013;13(6):721-8.
46. Goss G, Lu S, Felip E, et al. LUX-Lung 8: a randomized, open-label, phase III trial of afatinib vs. erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-based chemotherapy [abstract no. 509TiP]. Ann Oncol. 2012;23(Suppl 9):ix174.
47. Boehringer Ingelheim Pharmaceuticals. LUX-Lung 8: a phase III trial of afatinib (BIBW 2992) versus erlotinib for the treatment of squamous cell lung cancer after at least one prior platinum based chemotherapy [ClinicalTrials.gov identifier NCT01523587]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov/ct2/show/NCT01523587. Accessed 21 Oct 2013.
48. Boehringer Ingelheim Pharmaceuticals. LUX-Lung 7: a phase IIb trial of afatinib (BIBW2992) versus gefitinib for the treatment of 1st line EGFR mutation positive adenocarcinoma of the lung [ClinicalTrials.gov identifier NCT01466660]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov/ct2/show/NCT01466660. Accessed 21 Oct 2013.
49. Chen X, Zhu Q, Zhu L, et al. Clinical perspective of afatinib in non-small cell lung cancer. Lung Cancer. 2013;81(2):155-61.
50. Janjigian YY, Smit EF, Horn L, et al. Activity of afatinib/cetuximab in patients (pts) with EGFR mutant non-small cell lung cancer (NSCLC) and acquired resistance (AR) to EGFR inhibitors [abstract no. 12270]. Ann Oncol. 2012;23(Suppl 9):ix401.
51. Boehringer Ingelheim Pharmaceuticals. Trial of BIBW 2992 (afatinib) + cetuximab in non-small cell lung cancer [ClinicalTrials.gov identifier NCT01090011]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov/ct2/show/NCT01090011. Accessed 22 Oct 2013.
52. Langer CJ. Epidermal growth factor receptor inhibition in mutation-positive non-small-cell lung cancer: is afatinib better or simply newer? J Clin Oncol. 2013;31(27):3303-6.
53. De Grevè J, Teugels E, Geers C, et al. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer. 2012;76(1):123-7.
54. Boehringer Ingelheim Pharmaceuticals. LUX-Breast 2; afatinib in HER2 (human epidermal growth factor receptor)-treatment failures [ClinicalTrials.gov identifier NCT01271725]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov/ct2/show/NCT01271725. Accessed 23 Oct 2013.
55. Boehringer Ingelheim Pharmaceuticals. LUX-Breast 3; afatinib alone or in combination with vinorelbine in patients with human epidermal growth factor receptor 2 (HER2) positive breast cancer suffering from brain metastases [ClinicalTrials.gov identifier NCT01441596]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov/ct2/show/NCT01441596. Accessed 23 Oct 2013.
56. Boehringer Ingelheim Pharmaceuticals. LUX-Head&Neck 1: a phase III trial of afatinib (BIBW2992) versus methotrexate for the treatment of recurrent and/or metastatic (R/M) head and neck squamous cell cancer after platinum based chemotherapy [ClinicalTrials.gov identifier NCT01345682]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov/ct2/show/ NCT01345682. Accessed 23 Oct 2013.
57. Boehringer Ingelheim Pharmaceuticals. LUX-Head&Neck 2: a phase III trial of afatinib (BIBW 2992) versus placebo for the treatment of head and neck squamous cell cancer after treatment with chemo-radiotherapy [ClinicalTrials.gov identifier NCT01345669]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov/ct2/show/NCT01345669. Accessed 23 Oct 2013.
58. Boehringer Ingelheim Pharmaceuticals. LUX-Head&Neck 3: afatinib (BIBW2992) versus methotrexate for the treatment of recurrent and/or metastatic head and neck squamous cell cancer after platinum based chemotherapy [ClinicalTrials.gov identifier NCT01856478]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov/ct2/show/NCT01856478. Accessed 23 Oct 2013.